Marcela E. P. Pereira
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Marcela E. P. Pereira has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Amanda C. V. F. Silva
Laboratório de Campanha para Testagem e Pesquisa do COVID-19 (LCC), Instituto de Biodiversidade e Sustentabilidade (NUPEM), Universidade Federal do Rio de Janeiro (UFRJ), Macaé 27965-045, RJ, Brazil
1 shared publication - Amilcar Tanuri
Federal University of Rio de Janeiro
1 shared publication - Carina A. O. Silva
Laboratório de Campanha para Testagem e Pesquisa do COVID-19 (LCC), Instituto de Biodiversidade e Sustentabilidade (NUPEM), Universidade Federal do Rio de Janeiro (UFRJ), Macaé 27965-045, RJ, Brazil
1 shared publication - Cintia Monteiro de Barros
Laboratório Integrado de Biociências Translacionais, Instituto de Biodiversidade e Sustentabilidade – NUPEM Universidade Federal do Rio de Janeiro (UFRJ) Brazil
1 shared publication - Evenilton P. Costa
Laboratório de Campanha para Testagem e Pesquisa do COVID-19 (LCC), Instituto de Biodiversidade e Sustentabilidade (NUPEM), Universidade Federal do Rio de Janeiro (UFRJ), Macaé 27965-045, RJ, Brazil
1 shared publication - Flávia Borges Mury
Laboratório Integrado de Doenças Emergentes e Negligenciadas, Instituto de Biodiversidade e Sustentabilidade (NUPEM) - Universidade Federal do Rio de Janeiro (UFRJ), Macaé, Brazil
1 shared publication
Latest Publications
- Open Access
Immunoglobulin A as a Key Immunological Molecular Signature of Post-COVID-19 Conditions
COVID-19 has infected humans worldwide, causing millions of deaths or prolonged symptoms in survivors. The transient or persistent symptoms after SARS-CoV-2 infection have been defined as post-COVID-19 conditions (PCC). We conducted a study of 151 Brazilian PCC patients to analyze symptoms and immunoglobulin profiles, taking into account sex, vaccination, hospitalization, and age. Fatigue and myalgia were the most common symptoms, and lack of vaccination, hospitalization, and neuropsychiatric and metabolic comorbidities were relevant to the development of PCC. Analysis of serological immunoglobulins showed that IgA was higher in PCC patients, especially in the adult and elderly groups. Also, non-hospitalized and hospitalized PCC patients produced high and similar levels of IgA. Our results indicated that the detection of IgA antibodies against SARS-CoV-2 during the course of the disease could be associated with the development of PCC and may be an immunological signature to predict prolonged symptoms in COVID-19 patients.
Open AccessImmunoglobulin A as a Key Immunological Molecular Signature of Post-COVID-19 Conditions
COVID-19 has infected humans worldwide, causing millions of deaths or prolonged symptoms in survivors. The transient or persistent symptoms after SARS-CoV-2 infection have been defined as post-COVID-19 conditions (PCC). We conducted a study of 151 Brazilian PCC patients to analyze symptoms and immunoglobulin profiles, taking into account sex, vaccination, hospitalization, and age. Fatigue and myalgia were the most common symptoms, and lack of vaccination, hospitalization, and neuropsychiatric and metabolic comorbidities were relevant to the development of PCC. Analysis of serological immunoglobulins showed that IgA was higher in PCC patients, especially in the adult and elderly groups. Also, non-hospitalized and hospitalized PCC patients produced high and similar levels of IgA. Our results indicated that the detection of IgA antibodies against SARS-CoV-2 during the course of the disease could be associated with the development of PCC and may be an immunological signature to predict prolonged symptoms in COVID-19 patients.